FDA Issues Warning About Experimental MS Therapy

The U.S. Food and Drug Administration issued a warning about the potential risks of an experimental therapy used to treat a condition -- chronic cerebrospinal venous insufficiency, or CCSVI -- often linked to multiple sclerosis. CCSVI is characterized by a narrowing of veins in the neck and chest, and some researchers believe that the narrowing can lead to some of the central nervous system inflammation that is a hallmark of multiple sclerosis. "However, studies exploring a link between MS and...Full Story
Commenting on this article is closed.